Comment on: Systemic approach to managing vernal conjunctivitis in clinical practice and severity grading system and treatment algorithm Sir, We have read with keen interest the article -"Systematic approach to managing vernal keratoconjunctivitis (VKC) in clinical practice: Severity grading system and a treatment algorithm" by Dr. Nikhil S. Gokhale. [1] Although the article has enlightened us with a more meticulous way of treating vernal conjunctivitis, we have a few queries regarding the same.
1. The article does not mention any nonpharmacologic mean of managing vernal conjunctivitis apart from avoidance of allergen. Literature emphasizes the importance of avoidance of rubbing the eyes. It is known that rubbing causes histamine release, which further aggravates the condition [2] 2. The author has not mentioned washing face and eyes in the algorithm. Frequent washing of the face and eyes has been said to wash away the allergens, remove of cellular debris and toxic substances, and give symptomatic relief [3] 3. There is no emphasis on cold compression which enhances the effect of antihistaminics.
[4] It lowers the antigen-raised ocular surface temperature to less than the preexposure baseline and causes vasoconstriction, thus enhancing the local effect of drugs. VKC is often associated with ocular pruritus, and cold compresses give symptomatic relief in such cases [3] 4. Why did not the author specify use of preservative-free topical drops which reduce the risk of hypersensitivity to preservatives that are frequently superimposed in these patients 5. Why has the author highlighted the use of loteprednol over other steroids? It is said that fluorometholone is a more potent anti-inflammatory drug compared to loteprednol.
[5] Furthermore, fluorometholone has more efficacy in superficial ocular conditions while loteprednol is more efficacious in controlling intraocular conditions 6. What is the significance of lubricating eye drops in this condition? Their mechanism of action is same as that of washing eyes and face frequently along with cold compression. The patients already have a lot of watering, and there is no evidence of dry eye then how do we justify the use of artificial tears? 7. As per the algorithm, the author suggests that all the mentioned modes of treatment can be used in severe conditions. Does that mean we continue using antihistaminics in patients started with something as strong as tacrolimus? What is the treatment of choice to begin with in severe conditions according to the author? Can there be a more specific order of stepping up the treatment in severe conditions to make the article more pertinent? 
Authors' reply
Sir, Thanks for raising some very important questions and issues regarding my article. [1, 2] The article was not a review article to cover the entire gamut of management of vernal keratoconjunctivitis. Nonpharmacologic therapy and surgical management were not the main focus. The article was written to present a simple grading system and medical management scheme based on this grading system. The objective was to give a new insight onto how we could better treat severe allergies in our clinics.
Nonpharmacologic management was outside the purview and can be a separate article by itself. It includes allergen avoidance, protective goggles, hygiene, mite and mold control, air filtration systems, allergy testing and desensitization, and multiple environmental control interventions. Not rubbing the eyes, cold compresses, face washing, washing hands, etc., are indeed important factors as you have mentioned and are well known to most ophthalmologists.
The preservative-free lubricants are very helpful and always used in severe allergy; however, I am not aware of how they can reduce the risk of hypersensitivity to other preservatives used by the patients.
Loteprednol has been my preferred topical steroid because of its greater safety and lower potency to cause cataract and glaucoma. However, one could use fluorometholone, dexamethasone, and prednisolone eye drops in more severe cases if desired.
The low, long-term safety profile of traditional corticosteroids led to the development of modified corticosteroids such as loteprednol that retain the anti-inflammatory mechanism of action of traditional corticosteroids with a much-improved safety profile, because of their rapid breakdown to inactive metabolites after exerting their activity. Loteprednol etabonate has an ester (instead of a ketone) group at the carbon-20 (C-20) position of the basic corticosteroid structure. Clinical trials assessing this C-20 ester corticosteroid have revealed similar efficacy to C-20 ketone corticosteroids in the prevention or treatment of the signs and symptoms of seasonal allergic conjunctivitis, but with a greatly improved safety profile, as the C-20 ester corticosteroid is less likely to elevate intraocular pressure. In addition, the ketone at the C-20 position has been implicated in the formation of cataract while nonketolic corticosteroids do not form Schiff base intermediates with lens proteins, which is a common first step in cataractogenesis. Loteprednol etabonate offers a well-tolerated treatment option for patients with debilitating acute exacerbations as well as chronic forms of the disease. [3] Long-term data for more than 12 months are now available for use of loteprednol in allergic conjunctivitis.
[4] In another study, lotepredenol was as effective as prednisolone and more effective than fluorometholone, and it had no side effects during the short-term treatment of vernal keratoconjunctivitis patients. [5] Loteprednol has a lower propensity to cause intraocular pressure rise in steroid responders as compared to prednisolone. [6] On the other hand, 60.5% of steroid responder patients showed a rise in intraocular pressure of more than 5 mm Hg even after the use of fluorometholone. [7] A word of caution with regard to fluorometholone use in children is because of its higher propensity to cause a steroid response, especially when used at a higher frequency or for a longer period. [8] In severe allergies, we would still try allergen avoidance, lubricants, antihistaminics, and mast cell stabilizers because they would reduce the dosage needed for more potent immunosuppressive medications. A multipronged approach has to be used in these patients.
For severe cases, we need to start with multiple medications in the acute stage and then based on response to therapy further modify therapy. If there is a better algorithm that comes up in the future, I would be happy to put it into my practice.
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